Cambridge Healthtech Institute’s 9th Annual

Bioproduction: Scale, Bioreactors & Disposables
( 生物製造: Scale, Bioreactors & Disposables )

Making It Work



Cambridge Healthtech Institute’s “Bioproduction” conference reviews the finesse required to manufacture biologics including scale-down models, scaling up production, engineering bioreactors, single-use systems, and ensuring quality within the context of increasing productivity; while ensuring safety and achieving reduced costs.  A holistic review of bioprocessing will be explored, as well as practical details, such as monitoring and analyzing processes, and examining in detail how bioreactors process cells and how to keep those cells happy.  The conference will address robust production processes and next-generation technologies, while improving manufacturing platforms and ensuring product quality.

Final Agenda


7:00 am Registration Open and Morning Coffee


8:05 Chairperson’s Remarks

Jonathan Bones, PhD, Principal Investigator, Characterization and Comparability Laboratory, National Institute for Bioprocessing Research and Training (NIBRT)

8:15 KEYNOTE PRESENTATION: Next-Generation Processes – Scaling Up or Scaling Out

Maheshwari_GargiGargi Maheshwari, PhD, Associate Vice President, Merck & Co., Inc.

9:00 FEATURED PRESENTATION: Technical Trends and Concepts in Modern Bioprocessing Facilities

Schmidt_StefanStefan Schmidt, PhD, MBA, COO and Head, Operations, BioAtrium AG

Currently many new bioprocessing facilities are planned, constructed and commissioned. This talk gives an overview on trends in facility design; how to implement hybrid or modular solutions, and how to embed digital strategies like automation, PAT approaches, and paperless production already from the start. These concepts are explained through the example of a new commercial mammalian production plant.

9:30 Integrating PAT, Data Historian and Automation for Enhancing Process Understanding and Learning

Hamel_Jean-FrancoisJean-François Hamel, PhD, Research Engineer, Chemical Engineering, Massachusetts Institute of Technology (MIT)

This study seeks to compare how well manual sampling compares with automated sampling in a cell culture bioreactor interfaced with in situ and at-line instruments, and connected to a data historian by OPC. All samples are analyzed for the same analytes (e.g., substrates and metabolic products) and a correlation has been established between the two sampling procedures.

10:00 Coffee Break in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)


10:45 Presentation to be Announced

11:15 Development of an In-House Cell Free Extract Process and Robotic Platform for Expression Optimisation

Probert_PhilipPhilip Probert, PhD, Senior Upstream Scientist, Biologics, Centre for Process Innovation (CPI)

Use of cell-free protein expression in bioprocessing has traditionally been limited by low yields and high cost. To address these issues, we herein describe the development of a scalable lysate generation process, used in tandem with a high-throughput robotic screening method, as a platform for optimisation of cell-free expression, to support the development of robust and cost-effective cell-free manufacturing processes.

11:45 Presentation to be Announced

12:00 pm Sponsored Presentation (Opportunity Available)

12:15 Luncheon Presentation (Sponsorship Opportunity Available) or Enjoy Lunch on Your Own

1:00 Session Break


1:45 Chairperson’s Remarks


1:50 Production Bioreactor Scale-Down Model Verification Case Study

Michael Mollet, PhD, Principal Scientist, AstraZeneca

2:20 Bridging Scale-Down Model Learnings with Manufacturing Improvements: A Case Study

Discenza_JeremyJeremy Discenza, MSc, Scientist I, Bristol-Myers Squibb Co.

2:50 Cell Line and Process Sensitivities to Hypoxia in Chinese Hamster Ovary Cultures during Bioreactor Scale-Up

Xiaolin Zhang, PhD, Senior Scientist, Merck Pharmaceuticals

3:20 Efficient Scale-Up and Transfer of Manufacturing Processes

Amit Kumar Srivastava, MTech, Senior Manager, MSAT, Biologics Development Centre, Syngene International, Ltd.

Successful scale-up and establishment of a laboratory process in a manufacturing plant depends on a systematic approach considering engineering parameters as well as scientific and practical knowledge. The talk will go through examples of successful scale-up and technology transfer of manufacturing processes.

3:50 Refreshment Break in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)

4:45 Plenary Keynote Session View details

6:00 A Taste of New England Reception in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)

7:00 End of Day


8:00 am Registration Open and Morning Coffee


8:25 Chairperson’s Remarks

Stefan Schmidt, PhD, MBA, COO and Head, Operations, BioAtrium AG

8:30 Bench-Scale Single-Use Bioreactor Design and Optimization

Seamans_CraigT. Craig Seamans, PhD, Senior Principal Scientist, Biologics Process R&D, Merck & Co., Inc.

Here we report on optimized design 3-L rigid single-use bioreactors, coupled with automated sampling and feed control. Enhancements to bioreactor design include exploration of micro-sparger materials, along with utilization of CFD for establishing impeller and baffle configurations. The complete system can evaluate metabolic-based feed strategies for bench scale cell culture processes across multiple vessels, and implementation of the custom bioreactors and automated sampling has improved plant operational efficiency.

9:00 Disposable Systems for Bioreactor Harvest Clarification

Shenkman_RustinRustin M. Shenkman, PhD, Senior Upstream Development Engineer, Process Development Biologics, Shire US, Inc., a Takeda Company

Intensified bioreactor processes and the adoption of single-use manufacturing infrastructurehas put a strain on the harvest clarification unit operation. Legacy as well as recent technologies can provide several options for the rapid and efficient removal of cells and cellular debris from harvest streams. Development-scale evaluations were performed to compare promising technologies in yield and scalability and the results will be presented here.

9:30 Quality Versus Yield Trade-Off in Biosimilar Process Development: Lessons Learned

Havenga_MenzoMenzo Havenga, PhD, CEO, Batavia Biosciences

In generating high expressing biosimilar cell lines, we experienced the need to carefully check every step of the USP trajectory. This presentation will show two study cases where yield was compromised as quality is paramount.

9:45 Sponsored Presentation (Opportunity Available)

10:00 Coffee Break in the Exhibit Hall with Poster Viewing (Sponsorship Opportunity Available)


10:45 High Resolution Native LC-MS for Product CQA Assessment and Process Monitoring

Bones_JonathanJonathan Bones, PhD, Principal Investigator, Characterization and Comparability Laboratory, National Institute for Bioprocessing Research and Training (NIBRT)

Multi-attribute monitoring has attracted considerable attention recently as process scientists request more information to assist them to develop and understand their bioprocesses. A strategy for multi-attribute monitoring using intact protein separations coupled to native high resolution mass spectrometry will be described that facilitates the determination of multiple product quality attributes such as glycosylation, deamidation, lysine truncation, etc. Different examples will be presented along with strategies for inclusion of the platform in an online format.

11:15 Bioprocess Monitoring and Protein Quality Assessment Using Polarized Intrinsic Fluorescence Spectroscopy in Multi-Dimensional Modes: A New Measurement Methodology

Alan G. Ryder, PhD, Professor, Nanoscale Biophotonics Laboratory, Chemistry, National University of Ireland-Galway

Fluorescence polarization (or anisotropy) is related to protein structure, size, and aggregation profile. When implemented using multi-dimensional measurements on intrinsic protein emission, one can quickly extract potentially very useful diagnostic information. Here we show how polarized excitation-emission matrix (pEEM) measurements have been applied to the monitoring of IgG PEGylation reactions and how very similar pTSFS measurements when applied to bioreactor monitoring using a model system delivered significant improvements in accuracy.

11:45 A Computational Framework for Mechanistic Modeling and Simulation of Upstream Bioprocesses

Johnson_WillWill Johnson, PhD, Principal Engineer, Digital Integration & Predictive Technologies (DIPT), Process Development, Amgen, Inc.

The current benchmark for the digital transformation of upstream bioprocesses is computational fluid dynamics applied to bioreactors, which is limited by its consideration only of the fluid domain. Turning predictive bioreactor models into predictive bioprocess models requires a multiscale approach combining models of the bioreactor, cell physiology, and subcellular compartments. Here we introduce a computational framework for a digital predictive bioprocess model, and an exemplary model used to explore hypothetical changes to process setpoints with the goal of optimizing performance.

12:15 pm Enjoy Lunch on Your Own

1:15 Refreshment Break in the Exhibit Hall with Last Chance for Poster Viewing (Sponsorship Opportunity Available)

1:55 End of Conference

* 活動內容有可能不事先告知作更動及調整。